Delving into the Latest Updates on Shanghai Cell Therapy Research Institute with Synapse

Overview

This is a single-arm, open-label, one center clinical study, to determine the safety and efficacy of infusion of autologous T cells engineered to target mesothelin and express PD-1 antibodies in adult patients with advanced recurrent or refractory malignant solid tumors, which were positive expression of mesothelin.

Start Date06 Aug 2018

Sponsor / Collaborator

Shanghai Cell Therapy Research Institute

NCT03179007 / Unknown statusPhase 1/2IIT

A Clinical Study of CTLA-4 and PD-1 Antibodies Expressing MUC1-CAR-T Cells for Patients With MUC1 Positive Advanced Solid Tumors

This is a single-arm, open-label, one center clinical study, to determine the safety and efficacy of infusion of autologous T cells engineered to express immune checkpoint antibodies (CTLA-4 and PD-1) and chimeric antigen receptor targeting MUC1 in adult patients with MUC1 positive, advanced recurrent or refractory malignant solid tumors.

Start Date07 Jun 2017

Sponsor / Collaborator

Shanghai Cell Therapy Research Institute

NCT03182816 / Unknown statusPhase 1/2IIT

A Clinical Study of CTLA-4 and PD-1 Antibodies Expressing EGFR-CAR-T Cells for Patients With EGFR Positive Advanced Solid Tumors

This is a single-arm, open-label, one center clinical study, to determine the safety and efficacy of infusion of autologous T cells engineered to express immune checkpoint antibodies (CTLA-4 and PD-1) and chimeric antigen receptor targeting epidermal growth factor receptor (EGFR-CAR) in adult patients with EGFR positive, advanced recurrent or refractory malignant solid tumors.

Start Date07 Jun 2017

Sponsor / Collaborator

Shanghai Cell Therapy Research Institute

100 Clinical Results associated with Shanghai Cell Therapy Research Institute

Login to view more data

0 Patents (Medical) associated with Shanghai Cell Therapy Research Institute

Login to view more data

14

Literatures (Medical) associated with Shanghai Cell Therapy Research Institute

01 Jan 2024·Journal of Cancer

The effects of aging, sex, and tumor burden on the peripheral blood immune cell profile and absolute counts

Article

Author: He, Li ; Qian, Qijun ; Xiang, Kexin ; Xu, Zenghui ; Han, Donglei ; Ye, Zhenlong ; Tong, Ou ; Zhang, Yan ; Han, Zhongyang ; Sun, Yan

Background: To better assess the peripheral immune status and aid in the early diagnosis and prognosis of tumors, we compared the proportion and absolute counting of peripheral immune cell subsets in healthy individuals and tumor patients of varying ages, taking into account the impact of sex and tumor metastasis. Methods: We used peripheral blood mononuclear cell (PBMC) samples from 520 patients with various tumor types and 109 healthy volunteers. The absolute numbers of lymphocytes and monocytes were identified by an automated blood analyzer, and multi-parameter flow cytometry was used to examine the subsets of natural killer (NK) cells (CD3-CD16+CD56+), T cells (CD3+CD4+/CD8+), and mononuclear cells (CD14+) in PBMC. Results: The percentage of T cells (CD3+) in peripheral blood mononuclear cells (PBMC) was 55.83% VS 45.54% (P<0.0001) between healthy volunteers and tumor patients, showing a significant downward trend. Meanwhile, the percentages of monocytes (CD14+) and NK cells (CD3-CD16+CD56+) showed a significant upward trend. Single factor or multifactor analysis yielded identical findings on the proportion of PBMC between healthy individuals and patients with different malignancies, considering the three confounding variables of age, sex, and tumor metastasis. Conclusion: The proportion and absolute counting of acquired immune T cells, innate immune NK cells, and monocytes in PBMCs all exhibit substantial changes between cancer patients and healthy individuals, and the differences are influenced by age, sex, and tumor progression.

01 Dec 2020·Molecular Therapy - Methods & Clinical DevelopmentQ2 · MEDICINE

Safety and Efficacy of an Immune Cell-Specific Chimeric Promoter in Regulating Anti-PD-1 Antibody Expression in CAR T Cells

Q2 · MEDICINE

ArticleOA

Author: Qian, Qijun ; Fang, Yuan ; Chen, Chumeng ; Zhang, Yajun ; Zhou, Xiumei ; Gao, Haixia ; Guo, Chuanxin ; Liu, Tao

T cells modified to co-express cytokine or other factors with chimeric antigen receptor (CAR) can induce substantial and persistent increases in antitumor capacity in vivo. However, the uncontrolled expression of cytokines or factors can lead to the overactivation of immune cells, causing severe adverse events such as cytokine release syndrome (CRS) and neurotoxicity by CAR T cells with excessive growth potential. Conventional promoters are unregulated, and their expression is unlimited in T cells. In this study, by connecting the cytomegalovirus (CMV) enhancer, core interferon gamma (IFN-γ) promoter, and a T-lymphotropic virus long terminal repeat sequence (TLTR), we constructed and screened the chimeric promoter CIFT, which was highly expressed in some cell lines secreting IFN-γ and silenced in others. We placed this promoter upstream of the anti-programmed cell death protein 1 (anti-PD-1) antibody gene, and this construct was co-transfected with the CAR construct into T cells. In vitro or in vivo, CAR T cells showed increased secretion of anti-PD-1 antibody under control of the chimeric promoter CIFT. pS-CIFT-αPD-1/CAR T also had similar or lower PD-1 expression, higher levels of T cell activation, more release of IFN-γ, and better antitumor activity specifically against mesothelin-positive and PD-1 ligand 1 (PD-L1)-positive cell lines. The chimeric promoter may be a promising strategy to manipulate the content of immune checkpoint inhibitors or other proteins in future therapeutic approaches for cancer treatment.

01 Mar 2020·Translational Cancer ResearchQ4 · MEDICINE

Strategies for enrichment of circulating tumor cells

Q4 · MEDICINE

Review

Author: Ye, Zhenlong ; Shao, Wenqi ; Li, Zhong ; Li, You ; Zhao, Ren ; Li, Xinchun

Circulating tumor cells (CTCs) are cells derived from the primary sites of tumor patients into peripheral blood and serve as seeds that initiate tumor metastasis to distant sites. As a primary form of "liquid biopsy", CTC enumeration has exhibited great potential as a mean to obtain diagnostic and prognostic biomarker information in various cancers. The comprehensive clinical utility of CTC tests, however, is still restricted due to the scarcity and heterogeneity of CTCs, which necessitates reliable techniques for their efficient enrichment and characterization. Numerous methods have been developed to improve yield and purity of CTC enrichment as well as detection sensitivity. In this review, we comprehensively summarize techniques for CTC enrichment and detection.

100 Deals associated with Shanghai Cell Therapy Research Institute

Login to view more data

100 Translational Medicine associated with Shanghai Cell Therapy Research Institute

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 18 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Other

4

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

EGFR-CAR-T Cells(Shanghai Cell Therapy Research Institute) ( EGFR )	EGFR mutation Solid Tumors More	Pending
PD1-TIL(Shanghai Cell Therapy Research Institute) ( PD-1 )	Glioblastoma Multiforme More	Pending
Anti-CTLA4｜MUC1｜PD-1 CAR-T (Shanghai Cell Therapy Research ) ( CTLA4 x MUC1 x PD-1 )	MUC1 positive Solid Tumors More	Pending
PD-1 antibody expressing mesoCAR-T cells(Shanghai Cell Therapy Research Institute) ( MSLN x PD-1 )	Mesothelin positive Solid Tumors More	Pending